The promising effects of this compound in treating genetic diseases such as CMT2A suggests that activating MFN1/MFN2 may be a viable therapeutic option for reducing infection in instances where a pathogen induces mitochondrial fragmentation for survival. This evidence concerns the gene MFN2 and hereditary disease.